Zacks: Cortexyme, Inc. (NASDAQ:CRTX) Given Consensus Rating of “Buy” by Analysts
Shares of Cortexyme, Inc. (NASDAQ:CRTX) have been given a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company.
Brokerages have set a 1 year consensus price target of $41.67 for the company and are expecting that the company will post ($0.39) EPS for the current quarter, according to Zacks. Zacks has also given Cortexyme an industry rank of 80 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised Cortexyme from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a research note on Friday, January 3rd.
CRTX stock opened at $49.16 on Tuesday. The company has a 50-day simple moving average of $43.81 and a 200 day simple moving average of $32.10. Cortexyme has a fifty-two week low of $19.35 and a fifty-two week high of $72.94.
Cortexyme (NASDAQ:CRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). On average, analysts anticipate that Cortexyme will post -1.51 EPS for the current fiscal year.
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.
Featured Article: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.